Publisher's Synopsis
The author addresses the question who benefits most from treatment with recombinant human growth hormone in the field of paediatric endocrinology with the emphasis on evidence-based analysis of results and clear guidelines for clinical practice.;The principal childhood conditions associated with short stature, which could be amenable to beneficial long-term growth hormone treatment, have been covered. These include disorders associated with both insufficiency and sufficiency of growth hormone secretion.
